CYTOO Completes $10M Series C Funding

CYTOO SA, a Grenoble, France-based company specializing in cell-based assays, has completed a $10m (€7m) Series C funding.

The round was led by Sham and Entrepreneurs Fund, with participation from existing investors AURIGA Partners and Jacques Lewiner, CYTOO’s co-founder and president of the supervisory board.

The company intends to use the capital to brings its assays and screening to global markets and become profitable.

Led by CEO François Chatelain, CYTOO provides solutions designed to bring sensitivity and quantification to cell-based assays, high content analysis and cell screening for the life science research market.
The company holds an exclusive worldwide license from the Institut Curie and the CNRS (The French national scientific research center) for the adhesive micropattern patent portfolio, as well as license agreements with Harvard University (USA) and CEA, a government-funded technological research organization in France.



Join the discussion